Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/49517
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMARTENS, Pieter-
dc.contributor.authorVERBRUGGE, Frederik-
dc.date.accessioned2026-07-03T09:48:15Z-
dc.date.available2026-07-03T09:48:15Z-
dc.date.issued2026-
dc.date.submitted2026-07-03T09:45:06Z-
dc.identifier.citationJacc-heart Failure, 14 (6) (Art N° 103063)-
dc.identifier.urihttp://hdl.handle.net/1942/49517-
dc.description.sponsorshipDr Martens has received speaker and advisory fees from Abbott Laboratories, Bristol-Myers Squibb Belgium, Cytokinetics, and Novo Nordisk Pharma. Dr Verbrugge has received speaker and advisory fees from Abbott Laboratories, Abiomed, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb Belgium, Edwards Lifesciences, Johnson and Johnson, Menarini Benelux, Merck Sharp & Dohme, Novartis Pharma, Novo Nordisk Pharma, Pfizer and Qompium; has received travel grants from Abbott Laboratories,-
dc.language.isoen-
dc.publisherELSEVIER SCI LTD-
dc.rights2026 by the American College of Cardiology Foundation. Published by Elsevier.-
dc.subject.otherchronic kidney disease-
dc.subject.otherclinical trials-
dc.subject.otherheart failure with preserved ejection fraction-
dc.subject.othermineralocorticoid receptor antagonist-
dc.subject.otherpharmacotherapy-
dc.titleBalancing Efficacy and Safety With Finerenone in Patients With Heart Failure and Chronic Kidney Disease-
dc.typeJournal Contribution-
dc.identifier.issue6-
dc.identifier.volume14-
local.format.pages3-
local.bibliographicCitation.jcatA2-
dc.description.notesMartens, P (corresponding author), Ziekenhuis Oost Limburg AV, Dept Cardiol, Synaps Pk 1, B-3600 Genk, Belgium.-
dc.description.notesPieter.martens2@zol.be-
local.publisher.place125 London Wall, London, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedEditorial Material-
local.bibliographicCitation.artnr103063-
local.classdsPublValOverrule/author_version_not_expected-
dc.identifier.doi10.1016/j.jchf.2026.103063-
dc.identifier.pmid42230069-
dc.identifier.isi001788181100001-
local.provider.typewosris-
local.description.affiliation[Martens, Pieter] Ziekenhuis Oost Limburg AV, Dept Cardiol, Synaps Pk 1, B-3600 Genk, Belgium.-
local.description.affiliation[Martens, Pieter] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium.-
local.description.affiliation[Verbrugge, Frederik H.] Univ Hosp Brussels, Ctr Cardiovasc Dis, Jette, Belgium.-
local.description.affiliation[Verbrugge, Frederik H.] Vrije Univ Brussel, Fac Med & Pharm, Brussels, Belgium.-
local.uhasselt.internationalno-
item.fullcitationMARTENS, Pieter & VERBRUGGE, Frederik (2026) Balancing Efficacy and Safety With Finerenone in Patients With Heart Failure and Chronic Kidney Disease. In: Jacc-heart Failure, 14 (6) (Art N° 103063).-
item.fulltextNo Fulltext-
item.contributorMARTENS, Pieter-
item.contributorVERBRUGGE, Frederik-
item.accessRightsClosed Access-
crisitem.journal.issn2213-1779-
crisitem.journal.eissn2213-1787-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.